{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e81d0643b9a0dd40f9937b2/6afc8cc45a2e6307a89fa4e9?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What are the key considerations when delivering 1L treatment for AS cHL and how can AEs be managed?  ","description":"<p>The Lymphoma Hub was pleased to speak to Graham Collins, Oxford University Hospitals, UK. We asked, What are the key considerations when delivering 1L treatment for advanced-stage cHL and how can AEs be managed? </p><p><br></p><p>In this interview, Collins discusses the considerations guiding first-line (1L) treatment selection in advanced-stage classical Hodgkin lymphoma (cHL). He explores the evolving treatment landscape, highlighting the importance of balancing treatment efficacy and toxicity, fertility considerations, and patients’ individual priorities. </p><p><br></p><p>Intended for healthcare professionals. This educational resource is independently supported by Takeda Pharmaceuticals U.S.A., Inc. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. </p>","author_name":"Scientific Education Support"}